Align Technology (NASDAQ:ALGN) Receives Daily News Sentiment Rating of 0.23
Media stories about Align Technology (NASDAQ:ALGN) have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Align Technology earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 46.2353840071843 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Uptrend Call Working As Align Technology Stock Rises 78.1% (ALGN) (mysmartrend.com)
- Align Technology, Inc. (ALGN) Shares Bought by NGAM Advisors LP (overnewsmagazine.com)
- Align Technology, Inc. (ALGN) Updates Q3 Earnings Guidance (ismboard.com)
- Nevro’s (NVRO) Q2 Loss Wider than Expected, Revenues Beat – Nasdaq (nasdaq.com)
- Haemonetics Banks on Solid Plasma & Haemonetics Management – Nasdaq (nasdaq.com)
ALGN has been the topic of several research reports. Piper Jaffray Companies reiterated a “buy” rating and issued a $176.00 price target on shares of Align Technology in a research report on Friday, July 28th. Bank of America Corporation upgraded shares of Align Technology from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $175.00 to $193.00 in a research report on Friday, July 28th. Stifel Nicolaus reiterated a “buy” rating and issued a $200.00 price target (up from $145.00) on shares of Align Technology in a research report on Friday, June 23rd. Northcoast Research reiterated a “buy” rating and issued a $186.00 price target (up from $164.00) on shares of Align Technology in a research report on Wednesday, June 21st. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $150.00 price target (up from $110.00) on shares of Align Technology in a research report on Saturday, April 29th. Ten research analysts have rated the stock with a buy rating, Align Technology has a consensus rating of “Buy” and a consensus target price of $174.40.
Align Technology (NASDAQ ALGN) traded down 2.58% during mid-day trading on Thursday, reaching $171.23. The company’s stock had a trading volume of 1,084,667 shares. Align Technology has a 12 month low of $83.27 and a 12 month high of $176.84. The stock’s 50 day moving average is $158.81 and its 200 day moving average is $129.11. The company has a market cap of $13.72 billion, a price-to-earnings ratio of 58.64 and a beta of 1.55.
Align Technology (NASDAQ:ALGN) last released its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, topping the Zacks’ consensus estimate of $0.73 by $0.12. The company had revenue of $356.50 million for the quarter, compared to analyst estimates of $343.43 million. Align Technology had a return on equity of 23.87% and a net margin of 19.18%. Align Technology’s revenue was up 32.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.62 earnings per share. Equities research analysts predict that Align Technology will post $3.40 EPS for the current year.
In other news, VP Sreelakshmi Kolli sold 1,000 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $144.00, for a total transaction of $144,000.00. Following the sale, the vice president now owns 23,785 shares of the company’s stock, valued at $3,425,040. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Joseph Lacob sold 3,874 shares of the firm’s stock in a transaction dated Tuesday, May 30th. The stock was sold at an average price of $143.96, for a total value of $557,701.04. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,874 shares of company stock worth $7,950,701. 2.00% of the stock is currently owned by insiders.
About Align Technology
Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.
Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.